Author is bullish on IMRN, citing military/DoD backing, an imminent ProIBS launch, a phase 2 trial for IMM-200 in H1 2026, no dilution for a year, and a chart gap to fill.
IMRN — LONG The author argues IMRN is the next big biotech runner due to huge backing from the military and Department of Defense, with ongoing research relationships with major US military institutions. Catalysts cited include an imminent ProIBS launch (originally scheduled for Q4) and a phase 2 clinical trial for IMM-200 in the first half of 2026. The author also notes no dilution with cash for the next year and a large gap to fill on the daily chart from a 52-week high of $2.50 versus the current $1.00.
IMRN is a pharmacuetical play with huge backing by the military and department of defense.
This Reddit post, published January 13, 2026, features u/blakeley314 discussing IMRN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/blakeley314 · Tickers: IMRN